All In Biotech

Drug Trial Radar · NCT01685827

Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2

Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study

Last checked: Nov 20, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Title says "pivotal". Randomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

394

Actual

Start

Oct 2012

Primary completion

Nov 11, 2016

Study completion Apr 26, 2017

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 14, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to prove the efficacy and safety of Fexinidazole as an oral treatment for human african trypanosomiasis in advanced stage. The Fexinidazole is compared to reference treatment NECT. The trial will try to demonstrate that Fexinidazole is not inferior to NECT treatment.

Conditions

  • Human African Trypanosomiasis (HAT)
  • Sleeping Sickness

Interventions

  • FexinidazoleDrug

  • NifurtimoxDrug

  • EflornithineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. success or failure at 18 months FU visitTime frame: 18 months after treatment

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Batangafo

    Batangafo, Central African Republic

  • Bagata Hospital

    Bagata, Bandundu, Democratic Republic of the Congo

  • Dingila

    Dingila, Republic of the Congo

  • HGR (General Reference Hospital) Bandundu

    Bandundu, Bandundu, Republic of the Congo

  • HGR Mushie hospital

    Mushie, Bandundu, Republic of the Congo

  • Masi Manimba Hospital

    Masi Manimba, Bandundu - DRC, Republic of the Congo

  • Vanga Hospital

    Vanga, Bandundu - DRC, Republic of the Congo

  • CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital

    Mbuji Mayi, East Kasai, Republic of the Congo

  • HS Katanda hospital

    Katanda, Kasaï Oriental, Republic of the Congo

  • HGR ISANGI hospital

    Isangi, Province Orientale, Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.